Vaccine prospect of Kaposi sarcoma-associated herpesvirus.
Infection of Kaposi sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV-8) is estimated to account for 34,000 new cancer cases globally. Unlike other herpesviruses, KSHV is not ubiquitous but is highly prevalent in some areas, such as sub-Saharan Africa where Kaposi sarcoma is the leading cancer among adults. While latent infection of KSHV plays a major and direct role in tumorigenesis, viral lytic replication also makes significant contributions to this process. Efforts to develop a KSHV vaccine are limited, but studies with EBV have provided important lessons. Informative vaccine research has been conducted in the mouse infection model of a closely related rodent virus, murine gammaherpesvirus-68 (MHV-68 or γHV-68). This mouse model has generated fundamental principles for an effective vaccination strategy. KSHV vaccines designed to prevent a naïve host from infection and to boost the immune control of KSHV in persistently infected people will have major impact on individuals who are at a high risk of developing KSHV-associated diseases.
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, United States. twu@mednet.ucla.edu
Ting-Ting
TT
Wu
Jing
J
Qian
Jian
J
Ang
Ren
R
Sun
D000818:Animals; D004195:Disease Models, Animal; D019288:Herpesvirus 8, Human / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D022283:Herpesvirus Vaccines / Q000235:genetics / Q000276:immunology*; D006801:Humans; D012514:Sarcoma, Kaposi / Q000276:immunology / Q000517:prevention & control* / Q000821:virology
D022283:Herpesvirus Vaccines